Drug Facts
Composition & Profile
Identifiers & Packaging
How Supplied Cetacaine Topical Anesthetic Gel (Strawberry), 32 g jar NDC 10223-0217-3 Item# 0217 Cetacaine Topical Anesthetic Gel (Mint), 32 g jar NDC 10223-0221-1 Item# 0221; PRINCIPAL DISPLAY PANEL - 32 g Jar Box - Strawberry NDC 10223-0217-3 Item# 0217 Cetacaine ® Topical Anesthetic GEL (14% Benzocaine, 2% Butamben, and 2% Tetracaine Hydrochloride) Indicated for anesthesia of all accessible mucous membrane except the eyes. Strawberry Flavor Net Contents: 32 g Rev. 02/17 PRINCIPAL DISPLAY PANEL - 32 g Jar Box - Strawberry; PRINCIPAL DISPLAY PANEL - 32 g Jar Box - Mint NDC 10223-0221-1 Item# 0221 Cetacaine ® Topical Anesthetic GEL (14% Benzocaine, 2% Butamben, and 2% Tetracaine Hydrochloride) Indicated for anesthesia of all accessible mucous membrane except the eyes. Cool Mint Flavor Net Contents: 32 g Rev. 02/17 PRINCIPAL DISPLAY PANEL - 32 g Jar Box - Mint
- How Supplied Cetacaine Topical Anesthetic Gel (Strawberry), 32 g jar NDC 10223-0217-3 Item# 0217 Cetacaine Topical Anesthetic Gel (Mint), 32 g jar NDC 10223-0221-1 Item# 0221
- PRINCIPAL DISPLAY PANEL - 32 g Jar Box - Strawberry NDC 10223-0217-3 Item# 0217 Cetacaine ® Topical Anesthetic GEL (14% Benzocaine, 2% Butamben, and 2% Tetracaine Hydrochloride) Indicated for anesthesia of all accessible mucous membrane except the eyes. Strawberry Flavor Net Contents: 32 g Rev. 02/17 PRINCIPAL DISPLAY PANEL - 32 g Jar Box - Strawberry
- PRINCIPAL DISPLAY PANEL - 32 g Jar Box - Mint NDC 10223-0221-1 Item# 0221 Cetacaine ® Topical Anesthetic GEL (14% Benzocaine, 2% Butamben, and 2% Tetracaine Hydrochloride) Indicated for anesthesia of all accessible mucous membrane except the eyes. Cool Mint Flavor Net Contents: 32 g Rev. 02/17 PRINCIPAL DISPLAY PANEL - 32 g Jar Box - Mint
Overview
Active Ingredients: in a base consisting of polyethylene glycol, purified water, saccharin, cetyldimethylethylammonium bromide, flavoring and color Benzocaine 14.0% Butamben 2.0% Tetracaine Hydrochloride 2.0%
Indications & Usage
Indications Cetacaine Topical Anesthetic Gel is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. Cetacaine Topical Anesthetic Gel is indicated for use to control pain and for use for surgical or endoscopic procedures, or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus. It may also be used for vaginal or rectal procedures where feasible.
Dosage & Administration
Only a limited quantity of Cetacaine Topical Anesthetic Gel is required for anesthesia. Dispense 200 mg of gel (a bead approximately 1/4 to 1/2 inches long) by gently depressing the pump. Dispensing a bead of gel in excess of 400 mg is contraindicated. Spread thinly and evenly over the desired area using a cotton swab. In the unlikely event that a Cetacaine Gel pump jar won't dispense, attempt the following: Using a gloved hand, depress the pump fully using the thumb and middle finger. While depressed, cover the center orifice with the index finger. With the orifice still covered, slowly allow the pump to return to its original starting position. Repeat until Cetacaine Gel is dispensed (usually about 3-4 repeated attempts). An appropriate pediatric dosage has not been established for Cetacaine Topical Anesthetic Gel. Dosages should be reduced in the debilitated elderly, acutely ill, and very young patients. Do not use Cetacaine Gel to treat infants or children younger than 2 years. Tissue need not be dried prior to application of Cetacaine Topical Anesthetic Gel. Cetacaine Topical Anesthetic Gel should be applied directly to the site where pain control is required. Anesthesia is produced in approximately 30 seconds with an approximate duration of thirty to sixty minutes. Each 200 mg dose of Cetacaine Topical Anesthetic Gel contains 28 mg of benzocaine, 4 mg of butamben and 4 mg of tetracaine HCl.
Warnings & Precautions
Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs and symptoms of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Cetacaine and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.
Contraindications
Do not use Cetacaine Gel to treat infants or children younger than 2 years. Cetacaine is not suitable and should never be used for injection. Do not use on the eyes. To avoid excessive systemic absorption, Cetacaine Topical Anesthetic Gel should not be applied to large areas of denuded or inflamed tissue. Cetacaine Topical Anesthetic Gel should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinesterase deficiencies. Tolerance may vary with status of the patient. Cetacaine Topical Anesthetic Gel should not be used under dentures or cotton rolls, as retention of the active gel ingredients under a denture or cotton roll could possibly cause an escharotic effect. Routine precaution for the use of any topical anesthetic should be observed when using Cetacaine Topical Anesthetic Gel.
Drug Interactions
Patients that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following oxidizing agents: Class Examples Nitrates/Nitrites nitroglycerin, nitroprusside, nitric oxide, nitrous oxide Local anesthetics benzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine Antineoplastic agents cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea Antibiotics dapsone, sulfonamides, nitrofurantoin, para-aminosalicylic acid Antimalarials chloroquine, primaquine Anticonvulsants phenytoin, sodium valproate, phenobarbital Other drugs acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.